Prior SARS‐CoV‐2 infection balances immune responses triggered by four EMA‐approved COVID‐19 vaccines: An observational study

Lozano-Rodríguez, Roberto; Terrón-Arcos, Verónica; Montalbán-Hernández, Karla; Casalvilla-Dueñas, José Carlos; Bergón-Gutiérrez, Marta; Pascual-Iglesias, Alejandro; Quiroga, Jaime Valentín; Aguirre, Luis A.; Diego, Rebeca Pérez de; Vela-Olmo, Carmen; López-Morejón, Lissette; Martín-Quirós, Alejandro; Balzo-Castillo, Álvaro del; Peinado-Quesada, María A; García-Garrido, Miguel Ángel; Gómez-Lage, Laura; Herrero-Benito, Carmen; Llorente-Fernández, Irene; Martín-Miguel, Gema; Torrejón, Margarita; Cubillos‐Zapata, Carolina; Fresno, Carlos del; Avendaño-Ortíz, José; López-Collazo, Eduardo

doi:10.1002/ctm2.869

Cited by 4 publications

(1 citation statement)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mannose-modified lipid calcium phosphate nanoparticle vaccine is a novel tumor immunotherapy method that can enhance the immune response to tumors by regulating the tumor microenvironment [213]. Studies [214][215][216][217][218][219][220] have shown that the vaccine can activate the body's immune system, promote the expression and recognition of tumor-associated antigens, and trigger a specific immune response against tumor cells. Through mannose modification, the vaccine can be more effectively taken up by antigen-presenting cells and improve its efficiency of antigen delivery in the lymph nodes, further activating immune cells such as dendritic cells and T cells and enhancing the potential of the immune response [221].…”

Section: Enhancement Of Tumor Immune Response and Establishment Of Im...mentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as a potential therapeutic strategy. The potential role of the mannose-modified lipid calcium phosphate nanoparticle vaccine in enhancing the anti-tumor immune response was investigated. The aim of this study was to investigate the effect of mannose modification on the immune response of nanoparticles in regulating the tumor microenvironment through systematic review and analysis and to explore its potential clinical application in tumor therapy. Currently, despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and overexpression of immunosuppressive factors limit its clinical application. Therefore, this study will explore how to intervene in the immunosuppressive mechanism in the tumor microenvironment through mannose-modified lipid calcium phosphate nanoparticle vaccines so as to improve the immunotherapy effect of tumor patients and provide new ideas and strategies for the field of tumor therapy.

show abstract

Section: Enhancement Of Tumor Immune Response and Establishment Of Im...mentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionCOVID-19 vaccines based on mRNA have represented a revolution in the biomedical research field. The initial two-dose vaccination schedule generates potent humoral and cellular responses, with a massive protective effect against severe COVID-19 and death. Months after this vaccination, levels of antibodies against SARS-CoV-2 waned, and this promoted the recommendation of a third vaccination dose.MethodsWe have performed an integral and longitudinal study of the immunological responses triggered by the booster mRNA-1273 vaccination, in a cohort of health workers previously vaccinated with two doses of the BNT162b2 vaccine at University Hospital La Paz located in Madrid, Spain. Circulating humoral responses and SARS-CoV-2-specific cellular reactions, after ex vivo restimulation of both T and B cells (cytokines production, proliferation, class switching), have been analyzed. Importantly, all along these studies, the analyses have been performed comparing naïve and subjects recovered from COVID-19, addressing the influence of a previous infection by SARS-CoV-2. Furthermore, as the injection of the third vaccination dose was contemporary to the rise of the Omicron BA.1 variant of concern, T- and B-cell-mediated cellular responses have been comparatively analyzed in response to this variant.ResultsAll these analyses indicated that differential responses to vaccination due to a previous SARS-CoV-2 infection were balanced following the boost. The increase in circulating humoral responses due to this booster dropped after 6 months, whereas T-cell-mediated responses were more stable along the time. Finally, all the analyzed immunological features were dampened in response to the Omicron variant of concern, particularly late after the booster vaccination.ConclusionThis work represents a follow-up longitudinal study for almost 1.5 years, analyzing in an integral manner the immunological responses triggered by the prime-boost mRNA-based vaccination schedule against COVID-19.

show abstract

Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Yang,

Qian

et al. 2024

JFB

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as potential therapeutic strategies. A systematic review and analysis must be carried out to investigate the effect of mannose modification on the immune response to nanoparticles in regulating the tumor microenvironment, as well as to explore its potential clinical application in tumor therapy. Despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and the overexpression of immunosuppressive factors limit its clinical application. Therefore, our review explored how to intervene in the immunosuppressive mechanism in the tumor microenvironment through the use of mannan-decorated lipid calcium phosphate nanoparticle vaccines to improve the efficacy of immunotherapy in patients with tumors and to provide new ideas and strategies for the field of tumor therapy.

show abstract

Prior SARS‐CoV‐2 infection balances immune responses triggered by four EMA‐approved COVID‐19 vaccines: An observational study

Cited by 4 publications

References 10 publications

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals

Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment

Contact Info

Product

Resources

About